Clinical trials: Recurrent Tumor
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
This phase II trial studies how well copanlisib hydrochloride and nivolumab work in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma that has come back (recurrent) or does not…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT03484819
- Testing
- Copanlisib Hydrochloride, Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
This phase II trial is studying how well imatinib mesylate works in treating patients with locally recurrent or metastatic dermatofibrosarcoma protuberans (DFSP) or transformed fibrosarcomatous DFSP (a type of soft tissue…
- Conditions
- Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00084630
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Conditions
- Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- BMS-247550 (NCT00005807)
- Testing
- BMS-247550
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Albert Einstein College of Medicine
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- NCT06148636
- Testing
- [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- David Bushnell
Hodgkin Disease, Hodgkin Lymphoma
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
Background: Hodgkins lymphoma (HL) is a highly treatable cancer. However, if HL does not respond to chemotherapy or returns after chemotherapy, further treatments often are not successful.
- Trial name
- NCT01468311
- Testing
- Auto stem cell transplant, BEAM, 111In-daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Waldenstrom's Macroglobulinemia
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
- Trial name
- NCT00936611
- Testing
- LBH589
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill any remaining tumor cells following…
- Trial name
- NCT00053911
- Testing
- anastrozole, cyclophosphamide, docetaxel
- Where
- 26 sites in France
- Sponsor
- UNICANCER
Lymphoma
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with…
- Trial name
- NCT01909934
- Testing
- Brentuximab vedotin
- Where
- 40 sites in Belgium, Croatia and 8 more
- Volunteers
- 50 people
- Sponsor
- Takeda
Recurrent Glioblastoma
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
- Trial name
- NCT06598787
- Testing
- BL-B01D1 for Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Waldenstrom's Macroglobulinemia
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, PCI-32765, to learn whether PCI-32765 works in treating a specific cancer.
- Trial name
- NCT01614821
- Testing
- PCI-32765
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than fluorouracil for pancreatic cancer.
- Trial name
- NCT00005871
- Testing
- fluorouracil, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body.
- Trial name
- NCT02989636
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
The purpose of this research study is to look at the efficacy (the effect on tumor) and the safety (the effect on body) of the study drugs when given as a combination in patients with metastatic recurrent epidermal growth factor…
- Conditions
- HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
- Trial name
- NCT02892734
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Non-Muscle-Invasive Bladder Cancer
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or…
- Trial name
- NCT06327932
- Testing
- TURBT, HIVEC, Intravesical Chemotherapy
- Volunteers
- 320 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Leukemia, Myelodysplastic Syndromes
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory…
- Trial name
- NCT00003693
- Testing
- Dolastatin 10
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Barrett Esophagus, Esophageal Cancer
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable.
- Trial name
- NCT05056051
- Testing
- WATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Prostate Cancer
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
This is a prospective, multicentre, open-labelled, randomized controlled trial comparing the efficacy of immediate versus deferred androgen deprivation therapy (ADT) using goserelin (Zoladex®) in men with recurrent prostate…
- Trial name
- ELAAT (NCT00439751)
- Testing
- Goserelin Acetate
- Where
- 11 sites in Canada
- Volunteers
- 79 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Recurrent Urinary Tract Infection, Safety Issues
Controlled Human Urine Transfusion for UTI
The primary objective of this pilot study is to investigate the safety and tolerability of controlled human urine transfusion in female patients with recurrent UTI's.
- Trial name
- SHUTUP (NCT03142295)
- Testing
- urine transfusion
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Leiden University Medical Center
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.